Advances in the Development of Chimeric Antigen Receptor-T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia
Chimeric antigen receptor T (CAR-T)-cell therapy represents a groundbreaking advancement in the treatment of malignant tumors, particularly hematological malignancies. This review focuses on the application of CAR-T therapy in refractory/relapsed (R/R) B-cell acute lymphoblastic leukemia (B-ALL), highlighting its efficacy, current challenges, and future directions.
CAR-T cells are engineered by transducing T cells with a genetically modified CAR fusion protein using retroviral or lentiviral vectors. The CAR construct typically includes a single-chain variable fragment (scFv) antigen-recognition domain, a CD3-derived T-cell activation domain, and a costimulatory domain (CD28 or 4-1BB). These modified T cells are then infused into patients, often following a lymphodepleting conditioning regimen such as fludarabine and cyclophosphamide. The choice of costimulatory domain influences CAR-T cell behavior; CD28 enhances cytotoxic activity and early tumor eradication, while 4-1BB promotes persistence and memory T cell formation.
CD19-targeted CAR-T therapy has demonstrated remarkable efficacy in R/R B-ALL, achieving complete remission (CR) rates between 68% and 93%. This is a significant improvement over traditional chemotherapy, which offers CR rates of only 20% to 40%. The therapy has also shown promise in treating B-cell lymphoma and multiple myeloma, with CR rates of 53% to 67% and 60% to 90%, respectively. However, CAR-T therapy is not universally effective across all cancer types, with its greatest success observed in hematological malignancies.
Despite its high efficacy, CAR-T therapy is associated with significant side effects, primarily cytokine release syndrome (CRS) and CAR-T-related neurotoxicity. CRS, characterized by systemic inflammation, occurs in 18% to 100% of patients, with severe cases noted in 27% to 53%. Neurotoxicity, or immune effector cell-associated neurotoxicity syndrome (ICANS), manifests in 25% to 47% of patients. Management strategies include the use of tocilizumab, an IL-6 receptor antagonist, for CRS, and glucocorticoids for severe neurotoxicity. The severity of these side effects is influenced by the disease burden and the type of costimulatory domain used in the CAR construct.
One of the significant challenges in CAR-T therapy is the difficulty in collecting autologous T cells from patients with high tumor burdens or those who have undergone extensive chemotherapy. This has spurred interest in the development of universal CAR-T (UCAR) cells derived from healthy donors. UCAR cells aim to overcome issues of graft-versus-host disease (GVHD) and host-versus-graft rejection through innovative gene-editing technologies such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR-Cas9). These technologies allow for the knockout of endogenous T cell receptors (TCR) or HLA genes, facilitating the creation of off-the-shelf CAR-T products.
Relapse remains a significant issue post-CAR-T therapy, with approximately half of the relapses being CD19-positive and the other half CD19-negative. CD19-positive relapses are often due to the premature loss of CAR-T cells, while CD19-negative relapses result from the emergence of CD19-negative leukemic clones. Strategies to address relapse include the development of CAR-T cells targeting alternative antigens such as CD22 or dual-targeting CAR-T cells that recognize both CD19 and CD22. Sequential immunotherapeutic targeting and bridging to allogeneic hematopoietic stem cell transplantation (Allo-HSCT) post-CAR-T therapy have also been explored to improve leukemia-free survival (LFS).
The efficacy of CAR-T therapy varies among different high-risk subgroups of B-ALL patients. For instance, patients with TP53 mutations or the MLL-AF4 fusion gene exhibit lower CR rates compared to those without these genetic alterations. Additionally, patients with a high bone marrow blast count (>20%) or those who have previously received CAR-T or blinatumomab therapy are less likely to achieve CR. Despite these challenges, CAR-T therapy has shown promise in patients with extramedullary disease (EMD) and those who have relapsed post-Allo-HSCT.
The management of CAR-T-related adverse effects has become more refined with the development of diagnostic criteria and treatment guidelines. CRS is graded based on symptoms such as fever, hypotension, and hypoxia, with severe cases requiring interventions like tocilizumab and glucocorticoids. Neurotoxicity, characterized by symptoms ranging from confusion to seizures, is managed with sedatives and glucocorticoids. The dosage of infused CAR-T cells also plays a crucial role in balancing efficacy and toxicity, with lower doses showing promise in reducing severe adverse effects while maintaining high CR rates.
In conclusion, CD19-targeted CAR-T therapy has revolutionized the treatment of R/R B-ALL, offering high CR rates and durable remissions. However, challenges such as side effects, relapse, and the difficulty in autologous T cell collection persist. The development of universal CAR-T cells, multi-targeted CAR-T constructs, and strategies to bridge to Allo-HSCT hold promise for overcoming these challenges. As research progresses, CAR-T therapy is poised to become a more accessible and effective treatment option for a broader range of patients.
doi.org/10.1097/CM9.0000000000000638
Was this helpful?
0 / 0